Travis Steed
Stock Analyst
(3.01)
# 1,046
Out of 4,648 analysts
79
Total ratings
45.16%
Success rate
9.99%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EW Edwards Lifesciences | Downgrades: Neutral | $105 → $75 | $66.47 | +12.83% | 3 | Jul 25, 2024 | |
| SOLV Solventum | Maintains: Neutral | $70 → $60 | $72.17 | -16.86% | 2 | Jun 25, 2024 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $305 → $312 | $234.33 | +33.15% | 6 | May 6, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $35.80 | +25.70% | 5 | Mar 5, 2024 | |
| OM Outset Medical | Downgrades: Underperform | $32 → $3 | $0.62 | +383.56% | 1 | Oct 13, 2023 | |
| SYK Stryker | Upgrades: Buy | $315 | $366.90 | -14.15% | 5 | Sep 5, 2023 | |
| PODD Insulet | Maintains: Buy | $365 → $295 | $237.44 | +24.24% | 3 | Aug 24, 2023 | |
| AXGN Axogen | Reiterates: Overweight | $16 | $14.20 | +12.68% | 5 | Aug 22, 2023 | |
| TNDM Tandem Diabetes Care | Downgrades: Underperform | $45 → $33 | $32.85 | +0.46% | 2 | May 5, 2023 | |
| ZBH Zimmer Biomet Holdings | Upgrades: Neutral | $120 → $160 | $108.41 | +47.59% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $507.42 | -37.92% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $7.12 | +12.36% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $14.54 | +71.94% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 | $117.65 | +19.00% | 4 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $17.38 | +389.07% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $74 | $70.38 | +5.14% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $69.70 | +79.34% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $89.31 | +62.36% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $84.72 | -39.80% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $175 | $70.47 | +148.33% | 4 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $24.12 | +123.88% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $115.45 | -80.94% | 1 | Jul 17, 2017 |
Edwards Lifesciences
Jul 25, 2024
Downgrades: Neutral
Price Target: $105 → $75
Current: $66.47
Upside: +12.83%
Solventum
Jun 25, 2024
Maintains: Neutral
Price Target: $70 → $60
Current: $72.17
Upside: -16.86%
Becton, Dickinson and Company
May 6, 2024
Maintains: Overweight
Price Target: $305 → $312
Current: $234.33
Upside: +33.15%
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $35.80
Upside: +25.70%
Outset Medical
Oct 13, 2023
Downgrades: Underperform
Price Target: $32 → $3
Current: $0.62
Upside: +383.56%
Stryker
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $366.90
Upside: -14.15%
Insulet
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $237.44
Upside: +24.24%
Axogen
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $14.20
Upside: +12.68%
Tandem Diabetes Care
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $32.85
Upside: +0.46%
Zimmer Biomet Holdings
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $108.41
Upside: +47.59%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $507.42
Upside: -37.92%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $7.12
Upside: +12.36%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $14.54
Upside: +71.94%
May 31, 2022
Maintains: Buy
Price Target: $140
Current: $117.65
Upside: +19.00%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $17.38
Upside: +389.07%
Jul 12, 2021
Initiates: Overweight
Price Target: $74
Current: $70.38
Upside: +5.14%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $69.70
Upside: +79.34%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $89.31
Upside: +62.36%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $84.72
Upside: -39.80%
May 25, 2021
Initiates: Overweight
Price Target: $175
Current: $70.47
Upside: +148.33%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $24.12
Upside: +123.88%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $115.45
Upside: -80.94%